Similar articles

• Aromatase inhibitors for the treatment and prevention of breast cancer.

  Kalidas M, Brown P. Kalidas M, et al. Clin Breast Cancer. 2005 Apr;6(1):27-37. doi: 10.3816/CBC.2005.n.006. Clin Breast Cancer. 2005. PMID: 15899070 Review.
• The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.

  Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. Punglia RS, et al. Cancer. 2006 Jun 15;106(12):2576-82. doi: 10.1002/cncr.21919. Cancer. 2006. PMID: 16703595
• Recent advances in the hormonal treatment of breast cancer.

  Boughey JC, Buzdar AU, Hunt KK. Boughey JC, et al. Curr Probl Surg. 2008 Jan;45(1):13-55. doi: 10.1067/j.cpsurg.2007.10.004. Curr Probl Surg. 2008. PMID: 18206436 Review. No abstract available.
• Adjuvant chemotherapy for elderly women with hormone receptor-positive breast cancer: an old(er) problem.

  Schott A, Hayes DF. Schott A, et al. J Clin Oncol. 2004 Dec 1;22(23):4660-2. doi: 10.1200/JCO.2004.07.961. Epub 2004 Oct 25. J Clin Oncol. 2004. PMID: 15505274 No abstract available.
• Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.

  Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P, de Oliveira CT. Cataliotti L, et al. Cancer. 2006 May 15;106(10):2095-103. doi: 10.1002/cncr.21872. Cancer. 2006. PMID: 16598749 Clinical Trial.